EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

Andreas Reif iD, Istvan Bitter, Jozefien Buyze, Kerstin Cebulla, Richard Frey, Dong-Jing Fu, Tetsuro Ito iD, Yerkebulan Kambarov, Pierre-Michel Llorca, Albino J Oliveira-Maia iD, Thomas Messer, Siobhán Mulhern-Haughey und 5 weitere

New England Journal of Medicine · 05.10.2023 · 389 (14) · 1298-1309

DOI: 10.1056/nejmoa2304145 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 05.10.2023. Verfasst von Andreas Reif und 16 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Psychiatry, Psychosomatic Medicine, and Psychotherapy, University Hospital, Goethe University Frankfurt, and Fraunhofer Instit…. Hauptthemen laut MEDLINE: Antidepressive Agents, Quetiapine Fumarate, Selective Serotonin Reuptake Inhibitors, Serotonin and Noradrenaline Reuptake Inhibitors. Die Arbeit wurde bisher 233-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Janssen EMEA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsQuetiapine FumarateSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsKetamineDepressive Disorder, Treatment-ResistantHumansDelayed-Action PreparationsDepressionDrug Therapy, CombinationNasal SpraysRecurrenceSingle-Blind MethodTreatment Outcome

Substanzen

Antidepressive AgentsDelayed-Action PreparationsEsketamineNasal SpraysQuetiapine FumarateSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsKetamine

Autor:innen und Institutionen

  • From the Department of Psychiatry, Psychosomatic Medicine, and Psychotherapy, University Hospital, Goethe University Frankfurt, and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt (A.R.)…

ORCID-Profile: Andreas Reif, Tetsuro Ito, Albino J Oliveira-Maia

Förderung

  • Janssen EMEA

Zitieren

APA

Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D. J., Ito, T., Kambarov, Y., Llorca, P. M., Oliveira-Maia, A. J., Messer, T., Mulhern-Haughey, S., Rive, B., von Holt, C., Young, A. H., Godinov, Y., & ESCAPE-TRD Investigators (2023). Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. New England Journal of Medicine, 389(14), 1298-1309. https://doi.org/10.1056/nejmoa2304145

Vancouver

Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu DJ, et al. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. New England Journal of Medicine. 2023;389(14):1298-1309. doi:10.1056/nejmoa2304145

BibTeX
@article{Reif2023,
  author = {Reif, Andreas and Bitter, Istvan and Buyze, Jozefien and Cebulla, Kerstin and Frey, Richard and Fu, Dong-Jing and Ito, Tetsuro and Kambarov, Yerkebulan and Llorca, Pierre-Michel and Oliveira-Maia, Albino J and Messer, Thomas and Mulhern-Haughey, Siobhán and Rive, Benoît and von Holt, Christian and Young, Allan H and Godinov, Yordan and ESCAPE-TRD Investigators, ESCAPE-TRD Investigators},
  title = {Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {14},
  pages = {1298--1309},
  doi = {10.1056/nejmoa2304145}
}
Kostenlos starten →